Navigation Links
Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
Date:3/10/2008

.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)... Nov. 21 DNC Chairman T...Senate voted to begin full debate of health insura...newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) ,... the road to enacting health insurance reform. By ...ll now have an opportunity to debate the health re...
(Date:11/21/2009)...ovember 21, 2009 Test Te...st Test Test Test Test Test Test Test,Test Test Te...st Test Test,Test Test Test Test Test Test Test Te...est More test More test More test More test More t...est More test More test More,test More test , , ...
(Date:11/21/2009)... New Haven Dental Group merges their practice wi...T. , (PRWEB) November 21,...partners Dr. David Gibson, Dr. Dean Cloutier, Dr. ...erged their growing practice with that of esteemed...kman decided he wanted to retire from dentistry in...
(Date:11/20/2009)...TON, Nov. 20 The United...enate to make essential changes its health reform ...tion funding and conscience protection on abortion... include strong provisions for adequate affordabil...re bill an "enormous disappointment" that creates ...
(Date:11/20/2009)..., Nov. 20 Centene Corp...l present at the Bank of America Merrill Lynch 200..., at the Crowne Plaza Hotel Times Square in New Yo...ember 2nd at 8:30 a.m. Eastern Time. Investors and... webcast of Centene,s presentation at: http://www...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
... National Multiple Sclerosis Society Mid Jersey ...s to create one NJ Metro Chapter. Registration is... New Jersey (PRWEB) November 7, 2...a world free of multiple sclerosis. The chapter is...
...mmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) announ...r of a new entity, created by the American Orthopa...t-graduate orthopaedic fellowships and,residency p...alyze funding requests before making grants to,edu...
...n of attention-deficit hyperactivity disorder, res...ay News) -- Very young children who sustain a head...tention-deficit hyperactivity disorder (ADHD) late... Nov. 8 online edition of the British Medical Jou...
...r of veterans with posttraumatic stress disorder (... consequences on families and children in communit...u, Ph.D., an expert on veteran mental health and a...D. The Department of Veterans Affairs (VA) has men...
...ERIS Corporation,(NYSE: STE ) is postponing its a...lower attendance than anticipated. The Company bel...tion of its shareholder base can,attend is the mos...S Corporation is a leading provider of infection p...
... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ...and commercializing novel anti-infective products,...atag (amoxicillin,extended-release) Tablets, 775mg...ok President & CEO John Thievon said, "Public Law ...
Other Medicine News:Health News:National Multiple Sclerosis Society New Jersey Metro Chapter Looking for People to Join the Movement 2Health News:National Multiple Sclerosis Society New Jersey Metro Chapter Looking for People to Join the Movement 3Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3Health News:Head Injury in Young Kids May Predict ADHD Diagnosis 2Health News:Growing problem for veterans: Domestic violence 2Health News:STERIS Corporation Postpones Analyst Day 2Health News:STERIS Corporation Postpones Analyst Day 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 4
(Date:11/19/2009)...re/ -- In response to an ever-increasing number of...s, Operation Pangea II, involving 24 countries, wa...anization,s International Medical Products Anti-Co...angers of buying medicines online. ,, The week ...ests and the seizure of thousands of potentially h...
(Date:11/19/2009)...Newswire-FirstCall/ -- The D e al magazine has...mired Corporate Dealmakers for the second consecut...dmired Dealmaker in pharma/biotech for the most ef...ures since January 2006. ,, Over the past decad... a focus on high-growth, innovation-driven busines...
(Date:11/19/2009)...ewswire/ -- Breast-Specific Gamma Imaging/Molecula...d endorsed by two highly esteemed organizations fo...Breast Imaging (SBI) and the American College of S...ing the further application of this breakthrough i...t cancer. ,, "These endorsements reinforce what...
Breaking Medicine Technology:International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3Carl C Icahn Pleased With Results of Biogen Election 48534 1The CJ Foundation for SIDS Announces SLEEP IN SAFETY GROW IN STYLE Initiative 48530 1The CJ Foundation for SIDS Announces SLEEP IN SAFETY GROW IN STYLE Initiative 48530 2Longer Hormone Treatment May Improve Prostate Cancer Outlook 48526 1Longer Hormone Treatment May Improve Prostate Cancer Outlook 48526 2Longer Hormone Treatment May Improve Prostate Cancer Outlook 48526 3
...w Neo-Bladder Replacement Structurally Similar to,...ay 18 Press Briefing and ...N, Pa., May 19 Tengion,Inc., a clinical stage bio...eo-organs and neo-vessels, presented preclinical e...nt(TM) at the Annual Meeting of the American,Urolo...
...esented at the 2008 Annual European Congress of, R...st Rheumatism (EULAR) -, - Initiation of Phase 1 ... 2008 -, SAN DIEGO,...today announced the identification of its lead dev...ith gout, RDEA594. Gout is a,painful and debilitat...
Other Medicine Technology:Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5
...ates to adults, the entire series of time-tested T...surpassed knowledge of the needs of care providers...y. You can see it in the craftsmanship. You can se...meter® Classic Flowmeter is hand-crafted and e...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 1 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Medicine Products: